Ionis Pharmaceuticals
IONS
350 hedge funds and large institutions have $4.61B invested in Ionis Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 90 increasing their positions, 129 reducing their positions, and 31 closing their positions.
154% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $8.88M
65% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 31
5% more funds holding
Funds holding: 334 → 350 (+16)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.38% less ownership
Funds ownership: 88.23% → 87.84% (-0.38%)
0% less capital invested
Capital invested by funds: $4.63B → $4.61B (-$17.9M)
30% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 129
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$48.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.6M |
| 3 |
Renaissance Technologies
New York
|
+$18.1M |
| 4 |
O
OrbiMed
New York
|
+$17.1M |
| 5 |
BlackRock
New York
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$55.4M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$37.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$28.8M |
| 4 |
ClearBridge Investments
New York
|
-$17.7M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$11.3M |
IONS Hedge Fund Activity: Q2 2022 in Review
350 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2022, worth a combined $4.61B — down 0.39% from $4.63B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IONS positions and 31 closed out — a net gain of 20 holders — while 90 added to existing stakes and 129 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $48.1M. The largest seller was ARK Investment Management, cutting an estimated $55.4M.
- 350 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2022, up from 334 in Q1 2022.
- Funds reported $4.61B of Ionis Pharmaceuticals stock for Q2 2022, down 0.39% quarter-over-quarter.
- 51 funds opened new Ionis Pharmaceuticals positions in Q2 2022 and 31 closed out, a net change of +20 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2022 was BVF Inc, an estimated $48.1M added.
- The largest Ionis Pharmaceuticals seller in Q2 2022 was ARK Investment Management, an estimated $55.4M sold.
Based on aggregated 13F filings for Q2 2022.